Press Releases
  Date Title View
ROCKVILLE, Md., Aug. 15, 2017 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced, following a four-day bench trial, that the United States District Court for the District of New...
Posted: Aug 15, 2017
Second quarter net product sales were $73.3 million, a 46% increase over 2016.Strong acceleration in Trokendi XR prescription growth following April launch in migraine prophylaxis in adults and adolescents.Second quarter operating income was $26.1 million, a 124% increase over 2016.Raising full year 2017 financial guidance for net product sales by ...
Posted: Aug 2, 2017
ROCKVILLE, Md., July 19, 2017 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report the financial results for the second quarter of 2017 af...
Posted: Jul 19, 2017
ROCKVILLE, Md., June 21, 2017 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved MydayisTM (mixed salts of a ...
Posted: Jun 21, 2017
ROCKVILLE, Md., June 01, 2017 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company's management will present an overview and update for the Company, and host inve...
Posted: Jun 1, 2017
Net product sales were $56.4 million, a 31% increase over 2016.Operating income was $16.8 million, a 161% increase over 2016.Diluted earnings per share were $0.19, increasing by 138% over 2016.Early prescription data for Trokendi XR show a strong upward trend following launch in migraine prophylaxis in adults and adolescents. ROCKVILLE, Md., May ...
Posted: May 9, 2017
ROCKVILLE, Md., April 26, 2017 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report the financial results for the first quarter of 2017 af...
Posted: Apr 26, 2017
ROCKVILLE, Md., April 05, 2017 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Food and Drug Administration (FDA) has granted final approval to the Company's Supplem...
Posted: Apr 5, 2017
ROCKVILLE, Md., March 07, 2017 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, announced that it has entered into a binding term sheet with Actavis Laboratories, FL, Inc. et al. (collectivel...
Posted: Mar 7, 2017
ROCKVILLE, Md., March 06, 2017 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, announced that it has entered into a settlement agreement with Zydus Pharmaceutical (USA), Inc. and Cadila Heal...
Posted: Mar 6, 2017
1
...
NextLast
= add release to Briefcase